Phase 1Terminated

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Sponsor
Cogent Biosciences, Inc. (Industry)
Enrollment
26 enrolled
Conditions
Lymphoma
Interventions
ACTR707; rituximab
Ages
adults, older adults
Registry
NCT03189836

Full record on ClinicalTrials.gov

From the registry

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.

Primary outcomes

  • Safety as assessed by dose limiting toxicities (DLTs)
  • Determination of maximum tolerated dose and proposed recommended Phase 2 dose

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered